Panthera Biopartners

Delivery Certainty, built as a platform.

One integrated environment where our patient intelligence, in-house AI, live analytics and provable quality work as a single system. It makes your trial faster, more predictable and more transparent, across the UK, Hungary and beyond.

See what it is made of See what it does for you

Why it exists

Sponsors do not buy sites. They buy certainty.

Most site networks compete on geography and scale. We compete on certainty. Frictionless delivery is how we work; Delivery Certainty is what it produces. We remove the friction that slows a study down, not the rigour that protects it.

We cannot recruit patients fast enough.Slow identification of eligible people means late first patient in and an enrolment curve nobody trusts.

Patients enrol, then drop out.Missed visits create missing data, deviations and weaker statistical power.

The data we get is late and inconsistent.Fragmented reporting across sites and countries leaves no real-time view.

A quality failure could sink the submission.One critical finding can undo years of investment.

Multi-country delivery is fragmented.Manual handoffs and disconnected systems add risk at every stage.

What it is made of

One platform. Five pillars. Two foundations.

Select a pillar to open it. Each one answers one of the five problems above.

Foundation one

People

An established network of experienced principal investigators with deep therapeutic knowledge. Digital identifies and predicts; our people judge, select and deliver.

26 clinicians on our investigator database with cardiology and vaccine experience, as one example of depth in a single area
Clinical judgement that technology does not replace
A named clinical lead signs off every figure before it leaves us

Foundation two

Reach

Seven UK sites and four OEC sites in Hungary on one standard and one data platform, with Romania next. Central standards guarantee the baseline; local teams add the market knowledge.

One partner, one point of accountability
Clinic room time and patient-facing time measured monthly at every UK site, so headroom for a new study is a figure, not a promise
Keele opened in 2026 with eight rooms

What it does for you

Seven benefits, with the Pantheon at the centre.

Every spoke is a benefit the platform produces for the study you are running. Select a spoke to see what it means for you and which pillars it is built on.

Pantheon Instant Feasibility

A feasibility request goes in. A sourced response comes out.

A survey, a synopsis or a protocol is dropped in. The platform asks every system we run the questions a feasibility analyst would ask by hand, then drafts the response with every figure traced to its source. A named clinical lead signs it off.

In

Sponsor or CRO survey
Protocol or synopsis
Or just a study code

→

Asked, automatically

Our patient database: who, where, what they have applied for
Our clinical system: screening, randomisation and capacity by site
Our investigator database
Our feasibility history with that sponsor and CRO
NHS prescribing around every site
Independent trial and site records
Regulatory and programme rules

→

Out

The survey, answered
A feasibility response
Patient access and capacity workbooks
Investigator nominations
Competing studies and regulatory route
A provenance log for every figure

78,000+people aged 50 and over on our database, by site, for one recent cardiovascular vaccine request

950,000+statin prescriptions a month within 15 km of our UK sites, from NHS data

1,800+participants randomised across the UK network in the last twelve months

8systems and sources queried in one run, every answer with its source

Where it runs

One standard across countries.

The platform holds data from more than one country on one model, so a sponsor sees the same figures the same way in London, Budapest and, next, Bucharest.

7UK sites: Enfield, Glasgow, Keele, Preston, Rochdale, Sheffield, York

4OEC sites in Hungary: Budapest, Dunaujvaros, Kaposvar, Zalaegerszeg

NextRomania

One partner, one quality standard, one data platform across borders. Independent trial records give our UK sites completion rates between 79 and 100 percent and OEC 92 percent.

Why this is different

Assembled over years. Not available off the shelf.

A clinical asset, not a list

181,000 patient records enriched from every study we run. 53,000 people and more have attended one of our sites for a study visit.

One data layer, every country

APIs engineered in-house deliver consistent data across sites and countries. A patchwork of acquired systems cannot.

Intelligence owned outright

TrialTrack and the analytics layer are built and owned in-house. They get better with every study we run for you.

Quality you can audit

Zero critical findings across ten external audits and inspections since 2023, from a live quality tracker, not a claim.

Proven, repeatable scale

Hungary acquired and integrated on one playbook; Romania next.

Capacity you can see

Room occupancy and patient-facing time by site, from the clinical system, so headroom for a new study is a figure rather than a promise.